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Purpose: miR21, miR146, and miR155 represent a trio of microRNAs which has been shown to play a key role in the
regulation of immune and inflammatory responses. In the present study, we investigated the differential expression
and clinical significance of these three miRNAs in glioneuronal tumors (gangliogliomas, GGs) which are characterized
by prominent activation of the innate immune response.
Methods: The expression levels of miR21, miR146, and miR155 were evaluated using Taqman PCR in 34 GGs, including
15 cases with sufficient amount of perilesional cortex. Their expression was correlated with the tumor features and the
clinical history of epilepsy. In addition, in situ hybridization was used to evaluate their cellular distribution in both tumor
and peritumoral cortex.
Results: Increased expression of miR146a was observed in both tumor and peritumoral cortex compared to control
samples. miR146a was detected in both neuronal and astroglial cells. Tumor and peritumoral miR146a expression was
negatively correlated with frequency of seizures and the density of activated microglial cells. Neuronal and astroglial
expression was observed for both miR21 and miR155 with increased expression of miR21 within the tumor and miR155
in the peritumoral region. Negative correlations were observed between the miRNA levels and the expression of putative
targets within the astroglial component of the tumor.
Conclusion: We report a differential regulation of three miRNAs, known to be related to inflammation, in both tumor and
peritumoral cortex of patients with GG. Moreover, our findings suggest a functional relationship between miR146a
expression and epilepsy, either directly in epileptogenesis or as modulation of seizure activity.
Keywords: Gangliogliomas, miRNA, Real-time polymerase chain reactions, In situ hybridization,
Immunohistochemistry, Inflammation, EpilepsyIntroduction
Gangliogliomas (GGs) represent the most frequent
tumor entity in young patients who undergo surgery for
chronic intractable focal epilepsy [1, 2]. They are low-
grade, slowly growing, cortically based tumors included
within the group of long-term epilepsy associated tumor
(LEAT; [2]). GGs display a very low risk for tumor recur-
rence and malignant progression. Although surgical* Correspondence: e.aronica@amc.uva.nl
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unless otherwise stated.intervention shows favorable prognosis, both in terms of
tumor management and improving seizures, in a propor-
tion of cases, seizures may persist despite surgery [1–4].
Resection of tumor alone has been associated with a less
satisfactory outcome supporting the epileptogenic con-
tribution of the peritumoral zone [5, 6]. Histologically,
GGs are characterized by a mixture of dysmorphic neu-
rons and glial tumor cells. Recent studies have provided
evidence of a sustained inflammatory reaction in glio-
neuronal lesions with activation of both the innate and
adaptive immune response and involvement of different
inflammatory pathways, including the interleukin-1 re-
ceptor/Toll-like receptor pathway (IL-1R/TLR) [7–10].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sant and ictogenic properties of these pathways, support-
ing the role of inflammation in the pathophysiology of
human epilepsy (for review see [11–14]). Accordingly, it
has also been shown that the density of activated micro-
glia, as well as the number of IL-1β-positive neuronal
cells in focal cortical dysplasia (FCD) and in GG was
positively correlated with the frequency of seizures prior
to surgical resection [7, 15, 16].
In recent years, microRNAs (miRNAs) have been re-
ported as key post-transcriptional regulators of gene ex-
pression in several biological processes of the central
nervous system, as well as in the pathogenesis of differ-
ent neurological diseases and in oncogenesis [17–20].
Recently, both clinical and experimental studies have
shown the potential contribution of miRNAs to epilepsy
pathophysiology [21, 22]. miRNA array profiling studies
point to the role of microRNAs involved in inflammatory
processes [23–26]. During epileptogenesis in experimental
temporal lobe epilepsy [26], a significant upregulation of
miRNAs involved in the regulation of the IL-1R/TLR pro-
inflammatory pathway, including miR146a, miR21, and
miR155 [27–32], has been observed. Interestingly, miR146a
has been shown to be induced in response to inflammatory
cues as a negative-feedback regulator of the human
astrocyte-mediated inflammatory response [25].
In the present study, we investigated the expression
and cellular distribution of miR21, miR146, and miR155,
three miRNAs involved in the regulation of inflamma-
tory pathways with proictogenic properties [30], in a
large cohort of gangliogliomas with well-characterized
intractable epilepsy. In addition, we analyzed the expres-
sion of these miRNAs in the perilesional tissue, which is
of particular interest for its possible contribution to gen-
eration/propagation of seizures. To provide better in-
sights into the mechanisms underlying the intrinsic and
high epileptogenicity of these glioneuronal lesions, we
evaluated a possible relationship between changes in ex-
pression of these miRNAs, microglial activation, and the
clinical course of epilepsy.
Material and methods
Subjects
The cases included in this study were obtained from the
archives of the Department of Neuropathology of the
Academic Medical Center (AMC, University of Amsterdam)
and the University Medical Center in Utrecht (UMCU). A
total of 34 brain tissue specimens, removed from patients
undergoing surgery for intractable epilepsy, were exam-
ined. Tissue was obtained and used in accordance with
the Declaration of Helsinki and the AMC Research Code
provided by the Medical Ethics Committee and approved by
the science committee of the UMC Utrecht Biobank. All
cases were reviewed independently by two neuropathologists,and the diagnosis was confirmed according to the revised
WHO classification of tumors of the central nervous sys-
tem [33]. Thirty-two patients underwent resection of the
tumor for medically intractable epilepsy. The predominant
type of seizure pattern was that of complex partial seizures,
which were resistant to maximal doses of anti-epileptic
drugs (AEDs). The patients with epilepsy underwent pre-
surgical evaluation [34], and the post-operative seizure out-
come was classified according to Engel [35]. Twenty
patients underwent tailored temporal lobe epilepsy surgery.
The clinical features of the included GG patients are sum-
marized in Table 1. We included 15 GGs cases that con-
tained sufficient amount of peritumoral tissue (normal-
appearing cortex/white matter adjacent to the tumor), for
comparison with the autopsy specimens. Control cortex/
white matter from the temporal region was obtained at
autopsy from eight adult control patients without history
of neurological diseases (years/range, 25–52; female/male
(F/M), 4/4). Autopsy brain tissues from patients with
neuro-inflammatory pathologies (viral encephalitis; herpes
simplex encephalitis and rabies encephalitis) were also ex-
amined as positive controls. All autopsies were performed
within 12 h after death. Furthermore, we also used histo-
logically normal temporal neocortex from three male adult
patients (F/M, 2/1; years/range, 20–32) undergoing exten-
sive surgical resection of the mesial structures for the treat-
ment of medically intractable complex partial epilepsy.
Tissue preparation
Brain tissue from the control autopsy patients (n = 8) and
surgical tissue block from patients with GG were snap fro-
zen in liquid nitrogen and stored at −80 °C until further
use (RNA isolation for RT-PCR). Additional tissue was
fixed in 10 % buffered formalin and embedded in paraffin.
Paraffin-embedded tissue was sectioned at 5 μm, mounted
on pre-coated glass slides (Star Frost, Waldemar Knittel
GmbH, Brunschweig, Germany), and used for in situ
hybridizations and immunocytochemistry, as described
below. One representative paraffin block per case were
sectioned, stained, and assessed. Sections of all specimens
were processed for hematoxylin and eosin (HE), as well as
for immunocytochemical stainings for a number of neur-
onal and glial markers to confirm the diagnosis of
ganglioglioma.
In situ hybridization
In situ hybridization (ISH) for miR21, miR146a, and
miR155 were performed using a 5′ - 3′ fluorescein




Odense, Denmark). The hybridizations were done on
5 μm sections of paraffin-embedded materials as described
Table 1 Summary of clinical findings of GGs










1a,c F T 29 13 16 200 1a
2a,c M T 19 10 9 20 1a
3a,c M T 17 14 3 25 1a
4a,c F T 11 8 3 56 1a
5a,c M T 16 14 2 30 1a
6a,c M T 24 1 23 100 1a
7a,c F T 42 11 31 60 1a
8a,c M T 31 12 19 150 1a
9a,b,c M T 21 13 8 70 2a
10a,c F T 6 4 2 30 1a
11a,c F T 14 11 3 55 1a
12a,c M T 17 15 2 25 1a
13a,b,c F P 24 23 1 3 1b
14a,c F T 23 14 9 60 1a
15a,c F T 19 15 4 70 1a
16a M T 18 13 5 20 1a
17a,b M P 28 27 1 80 1b
18a M T 3 1 2 70 1a
19a F T 34 11 23 90 1a
20a F T 0.5 1 0.5 60 3a
21a M T 17 1 16 100 1a
22a M T 20 11 9 160 1a
23a F Fr 2 0. 25 2 70 1b
24a F T 31 22 9 40 1a
25a F T 33 8 25 90 1a
26a F T 49 19 30 150 NA
27b F T 22 10 12 20 1a
28b M T 34 16 18 10 1a
29b M T 33 18 15 50 1a
30b F T 56 52 4 60 2a
31b F T 28 12 16 80 2a
32b F Cer 48 No seizures – – –
33b M P 16 11 5 60 1b
34b F BS 29 No seizures – – –
M male, F female, Fr frontal, T temporal, P parietal, Cer cerebellum, BS brain stem
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(miR21) and 56 °C (miR146a and miR155) for 1 h, and the
hybridization was detected with alkaline phosphatase (AP)-
labeled anti-DIG (Roche Applied Science, Basel, Switzerland)
and AP-labeled anti-fluorescein (Roche Applied Science,
Basel, Switzerland). NBT (nitro-blue tetrazolium chloride)/
BCIP (5-bromo-4-chloro-3′-indolyphosphate p-toluidinesalt) was used as chromogenic substrate for AP. Negative
control assays were performed without probes and with-
out primary antibody (sections were blank). For the
double-staining, combining immunocytochemistry with in
situ hybridization, the sections were first processed for
ISH and then processed for immunocytochemistry with
glial fibrillary acidic protein (GFAP; monoclonal mouse,
Prabowo et al. Journal of Neuroinflammation  (2015) 12:97 Page 4 of 14Sigma, St. Louis, Mo, USA; 1:4000), NeuN (neuronal nu-
clear protein; mouse clone MAB377; Chemicon, Temecula,
CA, USA; 1:2000), (HLA)-DP, DQ, DR (mouse clone CR3/
43; DAKO, Glostrup, Denmark; 1:400), or CD34 (mouse
clone QBEnd10; Immunotech, Marseille, Cedex, France;
1:600). Signal was detected using the chromogen 3-amino-
9-ethylcarbazole (Sigma-Aldrich, St. Louis, MO, USA).RNA isolation
For RNA isolation, frozen material or cell culture mater-
ial was homogenized in Qiazol Lysis Reagent (Qiagen
Benelux, Venlo, The Netherlands). The total RNA includ-
ing the miRNA fraction was isolated using the miRNeasy
Mini kit (Qiagen Benelux, Venlo, the Netherlands) accord-
ing to manufacturer’s instructions. The concentration and
purity of RNA were determined at 260/280 nm using a
Nanodrop spectrophotometer (Ocean Optics, Dunedin,
FL, USA). Formalin-fixed paraffin-embedded (FFPE) ma-
terial was processed for RNA isolation using QuickEx-
tract™ FFPE (RNA Extraction Kit (Epicentre, Madison,
WI, USA) according to manufacturer’s instructions. The
concentration of RNA was determined using Qubit® 2.0
Fluorometer (Life Technologies, Carlsbad, CA, USA).Real-time quantitative PCR analysis (qPCR)
miRNA (miR21, miR146a, miR155, and the U6B small nu-
clear RNA gene, Rnu6B; miR23a) expression was analyzed
using Taqman microRNA assays (Applied Biosystems,
Foster City, CA). cDNA was generated using Taqman
MicroRNA reverse transcription kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instruc-
tions, and the PCRs were run on a Roche Lightcycler 480
thermo cycler (Roche Applied Science, Basel, Switzerland).Table 2 Immunohistochemistry: primary antibodies
Antigen Primary Antibody
Glial fibrillary acidic protein (GFAP) Polyclonal rabbit
Neuronal nuclear protein (NeuN) Mouse clone MAB37
Synaptophysin Mouse clone Sy38
Ki67 Mouse clone MIB-1
BRAF V600E VE1 clone
CD34 Mouse clone QBEnd
Phospho-S6 ribosomal protein (pS6) Monoclonal rabbit (
Human leukocyte antigen (HLA-DP, DQ, DR; MHC-II) Mouse clone CR3/43
IL-1β Polyclonal goat anti




MHC major histocompatibility complex
aKindly provided by D. Capper and A. von Deimling [39]Quantification of data was performed using the computer
program LinRegPCR in which linear regression on the Log
(fluorescence) per cycle number data is applied to deter-
mine the amplification efficiency per sample [36, 37]. The
starting concentration of each specific product was divided
by the starting concentration of reference gene (Rnu6B or
miR23a), and this ratio was compared between groups.
To evaluate the microRNA targets (IRAK1, IRAK2,
TNF receptor associated factor 6 (TRAF6), programmed
cell death 4 (PDCD4), SHIP1, ERBB4, MEF2C, NOTCH1,
NUMB, and phosphatase and tensin homolog (PTEN)),
five micrograms of total RNA (n = 10 GG; n = 8 controls)
were reverse-transcribed into cDNA using oligo dT
primers (see Additional file 1: Table S1).
Immunohistochemistry
Single-label immunohistochemistry (see Table 2) was
performed, as previously described [10, 38]. The sections
were deparaffinated in xylene, rinsed in ethanol (100 %,
95 %, 70 %), and incubated for 20 min in 0.3 % hydrogen
peroxide diluted in methanol. Antigen retrieval was per-
formed using a pressure cooker in 0.1 M citrate buffer
pH 6.0 at 120 °C for 10 min. Slides were washed with
phosphate-buffered saline (PBS; 0.1 M, pH 7.4) and incu-
bated overnight with the primary antibody in PBS at 4 °C.
Hereafter, the sections were washed in PBS and stained
with a polymer-based peroxidase immunocytochemistry
detection kit (PowerVision Peroxidase system, Immuno-
Vision, Brisbane, CA, USA). After washing, the sections
were stained with 3,3′-diaminobenzidine tetrahydrochlo-
ride (50 mg DAB, Sigma-Aldrich, Zwijndrecht, The
Netherlands) and 5 μl 30 % hydrogen peroxide in a 10-ml
solution of Tris–HCl. The sections were counterstained
with hematoxylin, dehydrated in alcohol and xylene, andSource Dilution
DAKO, Glostrup, Denmark 1:4,000
7 Chemicon, Temecula, CA, USA 1:2,000
DAKO Glostrup, Denmark 1:200
DAKO, Glostrup, Denmark 1:200
–a 1:5
10 Immunotech, Marseille, Cedex, France 1:600
Ser235/236) Cell Signaling Technology, Beverly, MA, USA 1:200
DAKO, Glostrup, Denmark 1:100
body Santa Cruz Bio., CA, USA 1:70
Sigma, St. Louis, Mo, USA, 1:300
Abcam, Cambridge, MA, USA 1:300
Abcam, Cambridge, MA, USA 1:450
Cell Signaling, Beverly, MA, USA 1:300
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antibodies or with pre-immune serum were essentially
blank. The sections were counterstained with hematoxylin.
Immunostaining for BRAF V600E (clone VE1, Spring
Bioscience, Pleasanton, CA, USA; [39]) was performed
on a Ventana BenchMark XT immunostainer (Ventana
Medical Systems, Tucson, AZ, USA).
Evaluation of histology and immunohistochemistry
All labeled tissue sections were evaluated by two inde-
pendent observers blinded to clinical data for the presence
or absence of various histopathological parameters and
specific immunoreactivity (IR) for the different markers.
Hematoxylin–eosin (HE) stained slides were used to
evaluate the neuronal and glial components of the tumors,
the presence of dysplastic neurons, calcifications, and
perivascular cuffs of lymphocytes. We also semi-
quantitatively evaluated the IR for the different markers,
such as synaptophysin, GFAP, CD34, and HLA-DR
(MHC-II). The intensity of IL-1β immunoreactive staining
was evaluated using a scale of 0–3 (0: −, no; 1: +/−, weak;
2: +, moderate; 3: ++, strong staining). All areas of the tu-
mors, as well the peritumoral cortex, were examined, and
the score represents the predominant cell staining inten-
sity found in each case. The frequency of IL-1β, TRAF6,
IRAK1, PDCD4, and SHIP1-positive cells [(1) rare, (2)
sparse, (3) high] was also evaluated to give information
about the relative number of positive glial cells within and
around the tumor. As proposed before [7, 40], the product
of these two values (intensity and frequency scores) was
taken to give the overall score (total score; total score; im-
munoreactivity score; IRS). The numbers of HLA-DR-
positive microglia/macrophages were quantified as previ-
ously described [15, 41].
Cell cultures
The astrocytoma cell line U373 was obtained from the
American Type Culture Collection (Rockville, MD,
USA); cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM)/HAM F10 (1:1) supplemented with
50 units/ml penicillin, 50 μg/ml streptomycin, and 10 %
FCS on poly-L-lysine-coated plates.
For astrocytes-enriched human cell cultures, fetal
brain tissue (15–20 weeks of gestation) was obtained
from spontaneous or medically induced abortions with
appropriate maternal written consent for brain autopsy.
Tissue was obtained in accordance with the Declaration
of Helsinki and the AMC Research Code provided by
the Medical Ethics Committee of the AMC. Resected tis-
sue samples were collected in DMEM/HAM F10 (1:1)
medium (Gibco, Life Technologies), supplemented with
50 units/ml penicillin and 50 μg/ml streptomycin and 10
% fetal calf serum (FCS). Cell isolation was performed as
previously described [25].Treatment of cell cultures
Human recombinant (r)IL-1β (Peprotech, NJ, USA; 10
ng/ml) was applied and maintained for 24 h before har-
vesting the cells for RNA isolation, as previously shown
[42], the viability of human astrocytes in culture was not
influenced by the treatments.
Statistical analysis
Statistical analyses were performed with SPSS for Windows
(SPSS 20, SPSS Inc., Chicago, IL, USA). Continuous vari-
ables were described with mean and ranges; categorical var-
iables with proportions and percentages. The two-tailed
Student’s t test or the non-parametric Kruskal–Wallis test
followed by the Dunn’s post hoc test was used to assess dif-
ferences between the groups. Correlation between immu-
nohistochemical and clinical features (duration of epilepsy,
seizure frequency, age at surgery, age at seizure onset, epi-
lepsy outcome, etc.) were assessed using the Spearman’s
rank correlation test. A value of p < 0.05 was defined as
statistically significant.
Results
Case material and histological features
The clinical features of the cases included in this study
are summarized in Table 1. Among the 34 patients (15
males and 19 females) included in the study, 32 had a
history of chronic pharmacoresistant epilepsy. Postoper-
atively, 30 out of 32 patients with epilepsy were com-
pletely seizure free (Engel’s class I). Thirty-two had
supratentorial tumors (n = 28 in temporal lobe). The
mean age at the time of surgery was 23.9 years (range
1–56; SD 12.9). The mean age at epilepsy onset was 13.2
years (range 0.25–52; SD 9.5); the mean pre-operative
seizure frequency was 67.6 per month (range 3–200; SD
45.9); and the mean duration of epilepsy was 10.5 years
(range 0.5–31, SD 9). BRAF V600E mutation was evalu-
ated in 33 GGs and detected in 15 cases (45.4 %).
miR21, miR146a, and miR155 expression by real-time
qPCR in GG and peritumoral cortex
miR21, miR146a, and miR155 expression was studied
using qPCR in control human cerebral cortex samples
and in GG samples. As previously shown for miR146a
[25], there were no significant differences in expression
between autopsy and surgical control samples, and
miRNA expression levels between paired frozen and FFPE
control samples were similar (not shown).
The expression of miR21, miR146a, and miR155 was
evaluated in both the frozen (Fig. 1; n = 9) and FFPE (Fig. 2;
n = 26) GG samples. Recent studies indicate a robust sta-
bility of miRNAs, supporting the accuracy of miRNA mea-
surements with RT-qPCR also in FFPE tissues [43, 44].
Expression of miR21 in frozen tissues was significantly




























Fig. 1 Quantitative real-time PCR of miR21, miR146a, and miR155 in
GG. Expression levels of miR21, miR146a, and miR155 in GG (n = 9;
frozen material). Data are expressed relative to the levels observed in
control cortex (n = 8, frozen material); miRNA expression was normalized
to that of the U6B small nuclear RNA gene (Rnu6B). The error bars
represent SEM; statistical significance: *p < 0.05; **p < 0.01
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sue; including 15 cases with perilesional cortex) showed
a tendency towards increased expression compared to
both control and peritumoral cortex (p = 0.5; Fig. 2).
Expression of miR146a in frozen tissue was significantly
higher in GG compared to control cortex (p = 0.002;
Fig. 1). Increased expression of miR146a was observed in
both the tumor and peritumoral cortex compared to the
control samples (FFPE material; p = 0.01; Fig. 2). There
was no significant difference in the expression of miR146a
between GG and peritumoral cortex.
Expression of miR155 in both frozen and FFPE tissue

























Fig. 2 miR21, miR146a, and miR155 expression levels in GG and peritumoral
(n = 26; formalin-fixed, paraffin-embedded, FFPE material) and peritumoral co
observed in control ctx (n = 5, FFPE); miRNAs expression was normalized to th
SEM; statistical significance: *p < 0.05; **p < 0.01. b Schematic representation(p = 0.1; Figs. 1 and 2). However, miR155 was highly
expressed in peritumoral cortex, showing a significant
difference compared to GG (p = 0.01; Fig. 2).
miR21, miR146a, and miR155 cellular distribution by in
situ hybridization in GG and peritumoral cortex
The cellular distribution of miR21, miR146a, and
miR155 in GG and peritumoral cortex was investigated
using in situ hybridization. In control cortex, miR146a
was expressed at low levels in neuronal cells but was un-
detectable in glial cells (Fig. 3a). miR146a expression was
increased in both tumor and peritumoral cortex. We de-
tected miR146a expression in cells with typical astroglia
morphology and in dysplastic neurons (Fig. 3b–d).
Double labeling confirmed miR146a expression in
NeuN- and GFAP-positive cells, whereas no detectable ex-
pression was observed in HLA-DR-positive cells of the
microglial/ macrophage lineage (Fig. 3b–d); miR146a was
also detected in BRAF V600E and IL-1β-positive cells
(Fig. 3d). miR146a was positively associated with miR155 ex-
pression within the tumor (r = 0.471, p = 0.018; Fig. 4a).
The tumor miR146a expression was negatively correlated
with the density of activated microglial cells (r = −0.400,
p = 0.043; Fig. 4b) and CD34 expression (r = −0.541,
p = 0.037; not endothelial cells). A positive correlation was
observed between miR146a expression in the peritumoral
cortex and GFAP IRS (r = 0.695, p = 0.004).
In both control and peritumoral cortex, miR21 was
mainly detected in neuronal cells (Fig. 3e, f ). In GG, the
expression of miR21 was increased and it was detected
in both neuronal and glial cells, as confirmed by double-






cortex. a Quantitative real-time PCR of miR21, miR146a, and miR155 in GG
rtex (ctx; n = 15; FFPE material). Data are expressed relative to the levels
at of the U6B small nuclear RNA gene (Rnu6B). The error bars represent
of miR21, miR146a, and miR155 changes in GG and peritumoral ctx
Fig. 3 (See legend on next page.)
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Fig. 3 In situ hybridization of miR146a, miR21, and miR155 expression in control, peritumoral cortex, and GG. a–d miR146a. a Control cortex
(−con); miR146a was expressed at low levels in neurons (arrows) and was undetectable in glial cells. b Peritumoral cortex (CTX-peri), showing
miR146a expression in neurons (arrows) and glial cells (arrowheads). c–d GG; miR146a was expressed in both the neuronal (arrows) and the glial
(arrowheads in d) tumor components. Inserts (a) in (b) and (c) show expression of miR146a in a neuron (NeuN positive, red); inserts (b) in (b) and
in (d) show colocalization (purple) of miR146a with GFAP (red). Insert (b) in c shows colocalization (purple) of miR146a with BRAF (red). Insert (a) in
(d) shows absence of colocalization with HLA-DR (microglia, red). Insert (c) in (d) shows colocalization (purple) of miR146a with IL-1β (red). e–g
miR21. In both control (e) and peritumoral cortex (f), miR21 was expressed at low levels in neurons (arrows) and was undetectable in glial cells. g
GG, showing miR21 expression in neurons (arrows) and glial cells (arrowheads). Insert (a) in (g) shows expression of miR21 in a neuron (NeuN
positive, red); insert (b) shows expression of miR21 in astrocytes (GFAP positive, red). h–j miR155. h Control cortex, showing low expression of
miR155. In peritumoral cortex (i), moderate expression was observed in neurons (arrows). j GG, showing miR155 expression in neurons (arrows)
and glial cells (arrowheads). Insert in i shows expression of miR155 in a neuron (arrow) and astrocytes (GFAP positive, red; arrowheads) around a
positive blood vessel. Insert (a) in j shows expression of miR155 in a neuron (NeuN positive, red); insert (b) shows expression of miR155 in an
astrocyte (GFAP positive, red; arrow) around a positive blood vessel (arrowheads); scale bar in (j): (a, c) 150 μm; (b, e–j) 80 μm; (d) 40 μm
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IRS (r = 0.396, p = 0.045). Expression of miR155 in con-
trol cortex was mainly observed in neuronal cells
(Fig. 3h). In peritumoral cortex and within the tumor,
miR155 was expressed in both neurons and glial cells
(NeuN- and GFAP-positive cells; Fig. 3i, j); we also ob-
served expression of miR155 in blood vessels (peritu-
moral cortex and tumor; Fig. 3i, j).
Regulation of miR21, miR146a, and miR155 expression by
IL-1β in cell culture
In the present study, we used both U373 glioblastoma
cells and fetal astrocytes in culture to examine the effect
of IL-1β on miR21, miR146a, and miR155 expression.
qPCR analysis demonstrated that exposure to IL-1β in-
creased miR21, miR146a, and miR155 expression in
U373 cells (Fig. 5a). Also, a tendency towards increased
extracellular miR21 levels was observed (Fig. 5b). In fetal
astrocytes, we observed a prominent upregulation of
both intracellular and extracellular miR146a (Fig. 5c, d).
miR21, miR146a, and miR155 expression and clinical
features in GG
We found no statistically significant association between
miR21, miR146a, and miR155 expression and clinicalFig. 4 miR146a expression in GG: correlation with miR155, number of HLA-DR
correlation between tumor miR146a expression and (a) tumor miR155 expressio
seizure frequency; r = Spearman’s rank correlation coefficient. *p < 0.05; **p < 0features, such as gender, age at surgery, location of the
tumor, or duration of epilepsy. However, a negative cor-
relation was observed between tumor and peritumoral
miR146a expression and the pre-operative seizure fre-
quency (GG: r = −0.454, p = 0.02; Fig. 4c; peritumoral
cortex: r = −0.538, p = 0.039).
miRNA target expression in GG
We evaluated the expression and cellular distribution of
PDCD4 (target of miR21), TRAF6 and IRAK1 (target of
miR146a), and SHIP1 (target of miR155) in GG by im-
munocytochemistry in the large cohort of samples
(FFPE, n = 26). Both PDCD4 and TRAF6 were
expressed in the astroglial component of the tumor
(Additional file 2: Figure S2A, B), and a negative correl-
ation was observed between the PDCD4 IRS and the
miR21 (r = −0.817, p = <0.001), as well as between the
TRAF6 IRS and the miR146a (r = −0.498, p = < 0.05).
Expression of TRAF6 was positively associated with the
pre-operative seizure frequency (r = 0.651, p = < 0.01), the
density of activated microglial cells (r = 0.522, p = < 0.01),
and the IL-1β IRS (r = 0.515, p = < 0.01). SHIP1 and
IRAK1 were expressed in both neuronal and glial cells
(Additional file 2: Figure S2C, D). There was a negative
correlation between miR155 and SHIP1 protein expression-positive cells and seizure frequency. Scatter plots showing the significant












































Fig. 5 miRNAs expression levels after exposure to IL-1β in culture. Quantitative real-time PCR. Cellular (a) and extracellular (b) levels of miR21, miR146a,
and miR155 in U373 glioblastoma cells 24 h after exposure to IL-1β (10 ng/ml). Cellular (c) and extracellular (d) levels of miR146a in human fetal astrocytes
in culture 24 h after exposure to IL-1β (10 ng/ml). Data are expressed relative to the levels observed in unstimulated cells and are mean ± SEM from two
cultures (*p < 0.05 compared to control). miRNAs expression was normalized to that of the U6B small nuclear RNA gene (Rnu6B) or to that of miR23a for
the intra- and extracellular fractions, respectively
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peritumoral cortex (r = −0.699, p = <0.05). IRAK1 expres-
sion was negatively correlated with miR146a (r = −0.560,
p = <0.05). No significant correlations were observed be-
tween miR155 and neuronal SHIP1, as well as between
miR146a and neuronal IRAK1.
Western blot analysis performed in a small cohort of
GG (n = 8) showed an increased expression of TRAF6
compared to controls and variable expression of IRAK1
and IRAK2 (Additional file 3: Figure S3); only a tendency
towards a negative correlation of miR146a with IRAK2
protein expression was observed (r = −0.587, p = 0.07).
Evaluation of mRNA expression levels of downstream
targets of miR21 (PTEN, PDCD4, and MEF2C), miR146a
(IRAK1, IRAK2 and TRAF6, ERBB4, NOTCH1, and
NUMB), and miR155 (SHIP1) showed significant down-
regulation of PTEN and NUMB mRNA expression in
GG compared to controls (data not shown; p < 0.001).
We also detected a negative correlation between PTEN
mRNA and the miR21 (r = −0.517, p = <0.04) and a ten-
dency towards a negative correlation between NUMB
mRNA and miR146a (r = −0.497, p = 0.0501).Microglial activation, IL-1β, and clinical features in GG
The density of activated microglial cells (HLA-DR-positive
cells) within the tumor was positively correlated with the
pre-operative seizure frequency (0.834, p < 0.001), theduration of epilepsy (0.631, p = 0.001), and the age at surgery
(0.521, p = 0.006); positive correlation was also observed with
the IL-1β IRS in both tumor and peritumoral cortex (0.838,
p < 0.001; 0.535, p = 0.04); Additional file 4: Figure S1A–C.
Expression of IL-1β in both tumor and peritumoral
cortex was positively associated with the pre-operative
seizure frequency (GG 0.855, p < 0.001; peritumoral ctx
0.579, p = 0.02) and the duration of epilepsy (GG 0.441,
p = 0.02; peritumoral ctx 0.669, p = 0.006); Additional
file 4: Figure S1D–F.
Discussion
GGs represent a major cause of medically intractable
epilepsy in young patients; however, the cellular mecha-
nisms underlying the intrinsic and high epileptogenicity
of these lesions remain to be fully investigated [1, 2].
Over the past decade, an increasing number of experi-
mental studies in animal models, as well as clinical and
neuropathological observations, obtained in human
brain specimens from various drug-resistant types of
epilepsy (including GGs), demonstrated the relevance of
inflammation in the pathophysiology of epilepsy (for re-
views see [11, 14, 45–47]). In particular, the IL-1R/TLR
proinflammatory pathway has been shown to critically
contribute to seizure development, and targeting proin-
flammatory pathways has been suggested as strategy to
obtain disease-modifying effects (i.e., decreased fre-
quency and severity of chronic seizure and reduced
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adaptive immune system with prominent activation of
proinflammatory proictogenic pathways (such as of the
IL-1R/TLR) has also been observed in GGs ([7–9, 15, 50]
present study). In this study, we provide additional evi-
dence of the activation of the Toll-like and interleukin-1
receptor (TIRs) signaling, showing increased expression of
downstream signaling molecules (IRAK1 and TRAF6) of
the TIR pathway.
Interestingly, the density of activated microglial cells has
been previously shown to be positively correlated with the
frequency of seizures prior to surgical resection and the
duration of epilepsy [15]. This observation has been con-
firmed in the present cohort, showing a positive correl-
ation between the IL-1β expression and pre-operative
seizure frequency, duration of epilepsy, as well as TRAF6
expression. A positive correlation was also observed be-
tween TRAF6 and the pre-operative seizure frequency, as
well as the density of activated microglial cells.
Since several inflammatory pathways have been shown
to be activated in concert in GGs [8], it is important to
identify and evaluate upstream master regulators (such
as miRNAs) of key proinflammatory/proictogenic path-
ways. In the present study, we investigated the expres-
sion and cellular distribution of miR21, miR146, and
miR155, three miRNAs involved in the regulation of IL-
1R/TLR proinflammatory/proictogenic pathway in a
large cohort of GGs. Our findings provide evidence of a
differential regulation of these three miRNAs both
within the tumor and in the peritumoral region, sup-
porting their potential active role in the clinical behavior
of the tumor. The cell-specific distribution of these miR-
NAs in relation with the epileptogenicity of the tumor is
discussed below.
miR21 expression and distribution in GG and peritumoral
cortex
Expression of miR21 has been observed in both tumor
and peritumoral cortex with a tendency towards increased
expression in the tumor compared to both control and
peritumoral cortex. Recent studies indicate expression of
this miRNA in both neuronal and glial cells [26, 51–53].
However, data about miR21 functions and cellular distri-
bution in human brain are still limited. We observed
neuronal expression in both control and peritumoral cor-
tex, whereas within the tumor, miR21 expression was de-
tected in both dysplastic neurons and tumor astrocytes.
miR21 has recently emerged as one of the important
dysregulated miRNAs in many pathological conditions, in-
cluding cardiovascular disease, brain injury, ischemia, and
in a variety of human neoplastic disorders, representing
the most commonly and strongly upregulated miRNA in
high-grade gliomas [54, 55]. Among the various targets of
miR21 are tumor suppressors such as phosphatase andtensin homolog (PTEN), programmed cell death 4
(PDCD4), components of the p53 pathway, or transform-
ing growth factor-β (TGF-β) signaling, resulting in in-
crease of cell proliferation, survival and migration/
invasion in tumors [54–56]. In our retrospective study, we
could not determine whether the expression levels of this
miRNA within the tumor would influence local recur-
rence on malignant transformation and evaluation of its
role in the regulation of astrocytes proliferation and differ-
entiation is still in progress. However, we observed a nega-
tive correlation between the expression of tumor PTEN
mRNA, as well as of PDCD4 protein in tumor astrocytes
and the level of tumor miR21, supporting the link between
miR21 and these targets. The positive correlation ob-
served between miR21 and the expression of tumor GFAP
supports the role of astrocytes as targets of regulation and
as a source of miR21.
Recently, miR21 has been shown to be upregulated in
animal models of temporal lobe epilepsy (TLE) after in-
duction of status epilepticus (SE) [26, 57]. In particular,
we have shown a significant increase of this miRNA in
three different hippocampal regions during the latent
period preceding the onset of seizure [26] and associated
with increased levels of proinflammatory cytokines, such
as IL-1β [58]. miR21 can be induced by NF-κB and has
been suggested to act as negative-feedback regulator of
Toll-like receptor signaling via targeting of the proin-
flammatory tumor suppressor PDCD4 ([59]; for review
see [31, 32, 55, 60]). However, in our study, only modest
increase was observed in glioma cells in response to IL-
1β and we did not find significant association between
miR21 expression and clinical features, such as pre-
operative seizure frequency or duration of epilepsy.
In addition, miR21 (as well as miR155) has been recently
shown to be upregulated in focal cortical dysplasia (FCD)
tissue samples [61] and in cortical tubers of patients with
tuberous sclerosis complex (TSC; van Scheppingen et al.,
unpublished observations), suggesting an epigenetic regu-
lation of the mammalian target of rapamycin (mTOR) sig-
naling pathway, which is also activated in GGs [10]. Thus,
a potential role for this miRNA in neuronal dysfunction
and mTOR activation can be considered and deserves fur-
ther investigation.
miR146a expression and distribution in GG and
peritumoral cortex
We confirmed, in a large tumor cohort, the previously
observed increased expression of miR146a in GG [25].
In situ hybridization showed increased expression of this
miRNA in tumor astrocytes and colocalization with IL-
1β was observed. Accordingly, IL-1β represents a major
inducer of this miRNA in both human astrocytes and
glioma cells ([25]; present data). Similar to miR21,
miR146a has also been shown to increase in reactive
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time of maximal astroglial activation [26, 62] and upreg-
ulation in astrocytes has also been reported in human
TLE [62, 63]. Recent studies support the function of this
miRNA as a key negative-feedback regulator of the
astrocyte-mediated inflammatory response (for reviews
see [31, 32]). In particular, miR146a overexpression has
been shown to reduce major inflammatory molecules in-
duced by IL-1β [25]. Accordingly, we observed a nega-
tive correlation between the level of tumor miR146a and
the expression of TRAF6, a downstream signaling mol-
ecule of the TIR signaling pathway that has previously
been shown to be a miR146 target. Interestingly, the ex-
pression of TRAF6 was positively associated with the
pre-operative seizure frequency.
In our cohort, the tumor miR146a expression was nega-
tively correlated with the density of activated microglial
cells. Moreover, we also observed a negative correlation
between tumor miR146a expression and the pre-operative
seizure frequency. Interestingly, alterations of miR146a
brain level have recently shown to modify acute seizures
in mice and to affect brain inflammation triggered by acti-
vation of the proictogenic IL-1R/TLR signaling pathway
([64]; unpublished observation), supporting the potential
for targeting this miRNA as strategy for modulating in-
flammatory pathways and seizure activity.
Secreted miRNAs may represent a new form of intercel-
lular communication, acting as signaling molecules [65–67]
and have been also shown to play a key role in the biology
of the tumor microenvironment [68]. In the present study,
we provide evidence of release of miR146a upon stimula-
tion with IL-1β in fetal human astrocytes in culture.
Surprisingly, miR146a is also expressed within the dys-
plastic and immature neuronal cell components of GG,
and we observed a negative correlation between the
levels of this miRNA and the expression of the precursor
cell marker, CD34 [69]. Interestingly, miR146a has been
recently shown to modulate neural stem cell prolifera-
tion and differentiation, and induction of this miRNA in
gliomas has been suggested to represent a negative-
feedback mechanism to restrict tumor growth [70]. Such
inhibitory function of miR146a on gliomas has been at-
tributed to the down-regulation of the key neural stem
cell factor NOTCH1 [70]. However, another key target
of mir146a is represented by NUMB [71, 72] that has
been shown to regulate cell fate and growth, acting as
tumor suppressor [73–75]. Interestingly, we observed a
down-regulation of NUMB in GG and a tendency towards
a negative correlation with miR146a. Thus, further study is
required to determine whether the expression levels of this
miRNA would differentially regulate proliferation and/or
differentiation of GG glial and neuronal components.
Moreover, since a mutation of the BRAF oncogene is fre-
quently observed in GGs [39, 50, 76, 77], its relationshipwith the expression of miR146a represents another aspect
that deserves attention. Accordingly, a recent study shows
that miR146a, upregulated by oncogenic BRAF, promotes
the initiation and progression of melanoma cells through
down-regulation of NUMB [78]. In our study, we observed
a colocalization with the BRAF V600E-mutated protein in
dysplastic neurons.
Increased expression of miR146a has been also observed
in the peritumoral cortex with expression in reactive as-
trocytes, and a positive correlation was observed between
miR146a levels and the expression of GFAP. Both clinical
and experimental studies support the epileptogenicity of
the peritumoral zone, which may contribute to the gener-
ation and propagation of seizure activity [79–81]. The
negative correlation observed between peritumoral
miR146a expression and the pre-operative seizure fre-
quency support the potential contribution of this miRNA
to the peritumoral epileptogenic network.miR155 expression and distribution in GG and
peritumoral cortex
miR155 has been extensively studied as a cancer-associated
miRNA and has been shown to be over-expressed in vari-
ous types of cancers (for review see [30, 56]). In particular,
it has been recently shown to promote glioma cell prolifer-
ation via the regulation of MXI1 [82] and GABA receptors
[83]. In our study, miR155 has been observed in both
tumor and peritumoral cortex, with increased expression
in peritumoral tissue compared to the tumor. In both
tumor and peritumoral cortex, we observed astroglial ex-
pression of miR155. Accordingly, this miRNA has been
shown to be expressed in human astrocytes and upregu-
lated in response to cytokines and TLR ligands [84]. In-
creased expression of this miRNA has been also reported
in multiple sclerosis lesions [85]. In our study, we showed
induction of miR155 in response to IL-1β in glioma cells.
Although miR155 has been shown to exert both positive
and negative effects on the NF-kB signaling proteins ([86];
reviewed in [30, 31]), in vitro studies support the positive
role in the induction of proinflammatory genes in human
astrocytes [84]. Thus, the expression of this miRNA ob-
served in the peritumoral area may counteract the anti-
inflammatory function of miR146. miR21 has been shown
to play an important role in the regulation of miR155 ex-
pression by promoting the expression of IL-10, a key nega-
tive regulator of miR155 expression [30, 31]. Interestingly,
low levels of expression were detected for miR21 in the
peritumoral cortex.
In both tumor and peritumoral cortex, expression of
miR155 has been also detected in endothelial cells. Accord-
ingly, miR155 has been shown to regulate endothelial cell
functions and angiogenesis and negatively affect blood–
brain barrier function during neuroinflammation [87–90].
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animal models of TLE [91, 92], as well as in FCD tissue
samples [61] and in TSC (van Scheppingen et al., unpub-
lished observations). In the present study, we did not
find a significant association between miR155 expression
and clinical features, such as pre-operative seizure fre-
quency or duration of epilepsy.
An issue to be considered in the interpretation of
these data is represented by the possible influence of
anti-epileptic drugs, such as valproate and phenobarbital,
on miRNAs expression [93, 94].
In conclusion, this study provides information on the
cellular distribution and expression of three inflammation-
related microRNAs in GGs. Our results indicate a dif-
ferential regulation of these miRNA involving also the
epileptogenic peritumoral region. In particular, the nega-
tive correlation observed between miR146a expression,
the density of activated microglial cells, and the pre-
operative seizure frequency support the potential role of
miR146a in regulating the clinical behavior of these epi-
leptogenic lesions, pointing to this upstream regulator of
proinflammatory/proictogenic pathways as attractive target
for further preclinical studies in drug-resistant epilepsies.
Additional files
Below is the link to the electronic supplementary material.
Additional file 1: Table S1. Real-time quantitative PCR analysis (qPCR;
microRNA targets).
Additional file 2: Figure S2. PDCD4, TRAF6, SHIP1, and IRAK1 expression
in GG. Representative photomicrographs of PDCD4 (A), TRAF6 (B), SHIP1, (C)
and IRAK1 (D) IR in GG showing expression in tumor astrocytes (arrows);
arrowhead in C shows neuronal expression of SHIP1 (C); insert in D: IRAK1
positive neuron (D). Sections were counterstained with hematoxylin. A–F:
scale bar: 40 μm.
Additional file 3: Figure S3. TRAF6, IRAK1, and IRAK2 protein expression.
Western blot analysis. A–C: representative immunoblot of total homogenates
from GG densitometric analysis: values (optical density units, O.D.) are mean
± SEM (n = 8), relative to the optical density of β-actin; *p < 0.05, compared
to controls (n = 6). (PPTX 72 kb)
Additional file 4: Figure S1. HLA-DR-positive cells and IL-1β expression
in GG: correlation with clinical variables. A–C: scatter plots showing the
significant correlation between HLA-DR-positive cells and (A) tumor IL-1β
immunoreactivity score (IRS; insert in A shows IL-1β IR within the tumor);
(B) pre-operative seizure frequency and (C) duration of epilepsy. D–F: Scatter
plots showing the significant correlation between tumor and (D) peritumoral
IL-1β IRS (insert in D shows IL-positive astrocytes within the peritumoral
cortex); (E) pre-operative seizure frequency and (F) duration of epilepsy;
r = Spearman’s rank correlation coefficient, *p < 0.05, **p < 0.01.
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